LSEG in talks to buy Permira-owned Octus data group for about $3.5 billion

LSEG confirmed talks with Permira to acquire Octus for about $3.5 billion; no final agreement has been reached and a transaction is not guaranteed. LSEG said the deal would immediately add to Data & Analytics and group revenue growth, while a deal at typical 12–14x enterprise-value-to-sales multiples could dilute EPS. LSEG shares fell 4.7% by 1342 GMT after declining more than 2% on an earlier report; Octus is expected to generate about $145 million of EBITDA this year and roughly $200 million next year.

Analysis

The market is pricing capital-allocation and execution risk, not just the strategic fit. On the reported figures, the roughly $3.5bn headline price equates to about 24x this-year or 17.5x next-year EBITDA only if the price is comparable to enterprise value; debt/cash, earn-outs and EBITDA adjustments could change that materially. Revenue accretion is not EPS accretion: financing costs, amortization and integration spend could dilute earnings even if cross-selling works. LSEG’s claim of immediate revenue-growth accretion therefore needs validation in the purchase terms and subsequent reporting.

In the next few days, expect sensitivity to any price or funding detail after the initial selloff. Over 1–3 months, the key catalyst is a signed deal with credible synergy and return disclosures; activist pressure raises the risk that investors judge the transaction against alternatives for capital deployment. Over 6–18 months, Octus could strengthen LSEG’s private-credit and distressed-data offering, but any benefit to Tradeweb or other channels depends on demonstrable customer conversion, not product adjacency alone. The private-data sale process may support sector asset marks, but does not establish a direct earnings benefit for Carlyle Group.

Contrarian view: the strategic asset may be more valuable inside a scaled distribution platform than standalone, so the selloff could overstate long-run integration risk. But without verified terms, the claimed growth benefit is easier to announce than to underwrite. Falsify the negative thesis if final terms show a materially lower effective multiple, limited balance-sheet strain and measurable cross-sell; reinforce it if guidance or EPS expectations are cut, leverage rises materially, or the deal terms expand.

Key Decisions for Investors

• Do not chase the initial LSEG selloff with an outright short. Maintain a modest relative underweight versus a broad UK-market benchmark until definitive price, funding and EPS-impact details are available; the first-day move may already discount some deal risk.
• Treat the stated EBITDA multiple as a diligence trigger, not a firm valuation: verify whether consideration is enterprise or equity value, Octus net debt, EBITDA adjustments, amortization and the funding mix before sizing exposure.
• Watch for a signed agreement and quantified cross-sell, retention and return metrics over the next 1–3 months. If LSEG provides credible per-share accretion after financing and integration costs, revisit the underweight; if guidance weakens or leverage meaningfully increases, retain or add to it.
• Do not infer a direct Carlyle Group earnings catalyst from the broader private-data sale activity. Any mark-up benefit depends on Carlyle’s actual exposure and transaction proceeds, which are not established here.